91 related articles for article (PubMed ID: 20048683)
1. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study.
Stremmel W; Braun A; Hanemann A; Ehehalt R; Autschbach F; Karner M
J Clin Gastroenterol; 2010; 44(5):e101-7. PubMed ID: 20048683
[TBL] [Abstract][Full Text] [Related]
2. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.
Stremmel W; Merle U; Zahn A; Autschbach F; Hinz U; Ehehalt R
Gut; 2005 Jul; 54(7):966-71. PubMed ID: 15951544
[TBL] [Abstract][Full Text] [Related]
3. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
5. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
6. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
8. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G
Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735
[TBL] [Abstract][Full Text] [Related]
10. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
12. Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis--a review of three clinical trials.
Stremmel W; Hanemann A; Braun A; Stoffels S; Karner M; Fazeli S; Ehehalt R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1623-30. PubMed ID: 21105858
[TBL] [Abstract][Full Text] [Related]
13. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
14. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
15. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis.
Celasco G; Papa A; Jones R; Moro L; Bozzella R; Surace MM; Naccari GC; Gasbarrini G
Aliment Pharmacol Ther; 2010 Feb; 31(3):375-86. PubMed ID: 19891665
[TBL] [Abstract][Full Text] [Related]
17. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis.
Thomas GA; Rhodes J; Ragunath K; Mani V; Williams GT; Newcombe RG; Russell MA; Feyerabend C
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):769-76. PubMed ID: 8864674
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.
Musch E; Andus T; Malek M; Chrissafidou A; Schulz M
Z Gastroenterol; 2007 Dec; 45(12):1235-40. PubMed ID: 18080224
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
Mantzaris GJ; Archavlis E; Christoforidis P; Kourtessas D; Amberiadis P; Florakis N; Petraki K; Spiliadi C; Triantafyllou G
Am J Gastroenterol; 1997 Mar; 92(3):454-6. PubMed ID: 9068468
[TBL] [Abstract][Full Text] [Related]
20. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
Marakhouski Y; Fixa B; Holomán J; Hulek P; Lukas M; Bátovský M; Rumyantsev VG; Grigoryeva G; Stolte M; Vieth M; Greinwald R;
Aliment Pharmacol Ther; 2005 Jan; 21(2):133-40. PubMed ID: 15679762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
